within Pharmacolibrary.Drugs.ATC.V;

model V08CA02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 7.5e-05,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0027,
    k12             = 4.2,
    k21             = 4.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V08CA02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Gadoteric acid is a gadolinium-based contrast agent (GBCA) used in magnetic resonance imaging (MRI) to enhance the quality of images. It is mainly indicated for visualization of lesions in the brain, spine, and associated tissues in adults and children. It is currently approved and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after a single intravenous bolus injection.</p><h4>References</h4><ol><li><p>Gheuens, E, et al., &amp; Mesens, S (2014). Dialysability of gadoteric acid in patients with end-stage renal disease undergoing hemodialysis. <i>Investigative radiology</i> 49(8) 505–508. DOI:<a href=\"https://doi.org/10.1097/RLI.0000000000000045\">10.1097/RLI.0000000000000045</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24619209/\">https://pubmed.ncbi.nlm.nih.gov/24619209</a></p></li><li><p>Fretellier, N, et al., &amp; Corot, C (2015). Distribution profile of gadolinium in gadolinium chelate-treated renally-impaired rats: role of pharmaceutical formulation. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 72 46–56. DOI:<a href=\"https://doi.org/10.1016/j.ejps.2015.02.016\">10.1016/j.ejps.2015.02.016</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25736527/\">https://pubmed.ncbi.nlm.nih.gov/25736527</a></p></li><li><p>Zhou, IY, et al., &amp; Gale, EM (2021). Positron Emission Tomography-Magnetic Resonance Imaging Pharmacokinetics, In Vivo Biodistribution, and Whole-Body Elimination of Mn-PyC3A. <i>Investigative radiology</i> 56(4) 261–270. DOI:<a href=\"https://doi.org/10.1097/RLI.0000000000000736\">10.1097/RLI.0000000000000736</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33136686/\">https://pubmed.ncbi.nlm.nih.gov/33136686</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V08CA02;
